Experimental antisense oligonucleotide
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Experimental antisense oligonucleotide, covering 2025-10-29 to 2025-10-29. Get the full timeline:
Most recent: Clinical Trial Update: An Open-label, Single Center, Single Participant Study of an Experimental Antisense Oligonucleotide Treatment for TUBB4A-related Leukodystrophy [Phase 1, Phase 2]